Millets National Media Portal
Millets National Media Portal
Emerging clinical evidence strongly supports millets as a key dietary intervention to halt and potentially reverse prediabetes — the stage of insulin resistance and elevated fasting glucose preceding full type 2 diabetes. Prediabetes is primarily characterized by insulin resistance and impaired glucose tolerance, both of which millets address directly. A 16-week randomized controlled trial published in PMC (2023) found that prediabetic participants consuming a millet-based diet (100g/day replacing refined grains) saw fasting plasma glucose normalize in 38% of participants, with mean HbA1c improving from 5.9% to 5.6%. This is particularly significant because a 0.3% reduction in HbA1c at the prediabetic stage is associated with a 30–40% reduction in progression to type 2 diabetes.
Key Points
100g/day of millet replacing refined grains normalized fasting plasma glucose in 38% of prediabetic participants in 16 weeks
Millet consumption reduces HOMA-IR (insulin resistance index) by 25–30%, addressing the core metabolic defect in prediabetes
High fiber content promotes weight loss of 1.5–2 kg over 12 weeks, which independently reduces insulin resistance
Magnesium in millets activates insulin receptor tyrosine kinase, restoring impaired insulin signaling in muscle and liver cells
Replacing refined grains with millets reduces the daily dietary glycemic load by 30–40%, the single most impactful dietary change for prediabetics
Evidence Base
PMC (2023) 16-week RCT and Frontiers in Nutrition (2021) meta-analysis provide Level I evidence that millet-based dietary interventions can normalize prediabetic markers in a significant proportion of patients, positioning millets as a first-line dietary strategy for diabetes prevention.
© 2023 - 2026 Millets News. All rights reserved.
